MetaCap

Candel Therapeutics (CADL) vs IRulya Therapeutics (IRLA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IRulya Therapeutics is the larger company by market cap ($432.4 million vs $395.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CADL-57.00%IRLA+17.16%
+23%-19%-61%
Aug 14, 20261 yearNov 20, 2026
CADL-57.00%IRLA+17.16%
+21%-20%-61%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CADL versus IRLA key metrics
MetricCADLIRLA
Share price$5.04$39.88
Market cap$395.37M$432.36M
1-day change-1.75%-0.15%
YTD return-10.80%—
1-year return+10.77%—
5-year return-48.47%—
EPS (TTM)$-1.53$-162.79
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-38.18M$-83.98M
52-week high$14.00$910.00
52-week low$4.35$15.10
Distance from 52-week high-64.00%-95.62%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+250.60%+90.90%
Average volume1.26M63.03K
Shares outstanding78.45M10.84M
Employees5538
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Candel Therapeutics

CADL stock →

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

CADL vs IRLA FAQ

Which is bigger, Candel Therapeutics or IRulya Therapeutics?

IRulya Therapeutics (IRLA) is larger, with a market capitalization of $432.36M compared with $395.37M for Candel Therapeutics (CADL).

Are Candel Therapeutics and IRulya Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons